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Background: The prevalence of bacterial bloodstream infections (BSIs) in sub-Saharan Africa (sSA) is high and
antimicrobial resistance is likely to increase mortality from these infections. Third-generation cephalosporin-re-
sistant (3GC-R) Enterobacteriaceae are of particular concern, given the widespread reliance on ceftriaxone for
management of sepsis in Africa.
Objectives: Reviewing studies from sSA, we aimed to describe the prevalence of 3GC resistance in Escherichia
coli, Klebsiella and Salmonella BSIs and the in-hospital mortality from 3GC-R BSIs.
Methods: We systematically reviewed studies reporting 3GC susceptibility testing of E. coli, Klebsiella and
Salmonella BSI. We searched PubMed and Scopus from January 1990 to September 2019 for primary data
reporting 3GC susceptibility testing of Enterobacteriaceae associated with BSI in sSA and studies reporting mor-
tality from 3GC-R BSI. 3GC-R was defined as phenotypic resistance to ceftriaxone, cefotaxime or ceftazidime.
Outcomes were reported as median prevalence of 3GC resistance for each pathogen.
Results: We identified 40 articles, including 7 reporting mortality. Median prevalence of 3GC resistance in E. coli
was 18.4% (IQR 10.5 to 35.2) from 20 studies and in Klebsiella spp. was 54.4% (IQR 24.3 to 81.2) from 28 studies.
Amongst non-typhoidal salmonellae, 3GC resistance was 1.9% (IQR 0 to 6.1) from 12 studies. A pooled mortality
estimate was prohibited by heterogeneity.
Conclusions: Levels of 3GC resistance amongst bloodstream Enterobacteriaceae in sSA are high, yet the
mortality burden is unknown. The lack of clinical outcome data from drug-resistant infections in Africa represents
a major knowledge gap and future work must link laboratory surveillance to clinical data.
Introduction
The emergence and spread of antimicrobial resistance (AMR) in
bacteria is recognized as a global public health problem.1 Drug-
resistant infections (DRIs) caused by AMR bacteria threaten human
health worldwide, with the greatest mortality burden expected to
occur in low- and middle-income countries.2 In settings where
antibiotics and advanced diagnostics are available and affordable,
DRIs can be treated with tailored regimens using second- or third-
line antibiotics; however, these agents cost more and increase
healthcare expenditure.3 In sub-Saharan Africa (sSA), where
bacterial bloodstream infection (BSI) is a major cause of morbidity
and mortality,4 diagnostic facilities are scarce and antibiotics such
as carbapenems and semi-synthetic aminoglycosides (e.g. amika-
cin) are either unavailable or prohibitively expensive, the morbidity
and mortality from DRIs is predicted to be high.2,5
In many sSA hospitals, limited nursing capacity favours the
use of broad-spectrum antimicrobials with a once-daily dosing
regimen and this has led to the widespread adoption of the
third-generation cephalosporin (3GC) ceftriaxone for the empirical
management of hospitalized patients with suspected sepsis.6
VC The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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ESBL-producing Enterobacteriaceae, which are resistant to penicil-
lins and 3GCs, represent a threat to the treatment of BSI in this set-
ting and have been identified as priority pathogens on which all
national AMR programmes should focus their surveillance and
reporting.2,7
Comprehensive AMR surveillance in sSA is limited by lack of
quality-assured diagnostic microbiology laboratories, but know-
ledge of the prevalence and spatiotemporal trends of 3GC-
resistant (3GC-R) Enterobacteriaceae is critical to inform national
and international antibiotic prescribing guidelines. Additionally,
securing access to effective second- and third-line antibiotics in
Africa will not only require an understanding of the prevalence of
3GC resistance, but also of the burden and impact of these patho-
gens on patients and healthcare systems.8 We have therefore sys-
tematically reviewed published reports of 3GC susceptibility
amongst key Enterobacteriaceae in sSA, including surveillance
data and clinical cohorts. Robust clinical outcome data are needed
to support the estimates and assumptions that the greatest global
burden associated with AMR will occur in sSA5 and we have there-
fore also reviewed studies that describe mortality from 3GC-R BSI.
The aim of this systematic review was to determine the prevalence
of 3GC resistance amongst Escherichia coli, Klebsiella spp. and
Salmonella BSI in sSA and to provide an estimate of the associated
mortality burden from these infections.
Methods
Search strategy and selection criteria
We systematically reviewed articles published between 1 January 1990
and 31 August 2019, according to a pre-specified protocol, prepared in
February 2017 (Table S1, available as Supplementary data at JAC Online)
with no language restrictions, following PRISMA guidelines (Table S2). We
searched PubMed and Scopus according to a predefined strategy with
search terms relating to BSI and susceptibility testing (Table S3). A search
string that included all sSA countries as defined by the UN list of 54 African
sovereign states returned more articles than a string using ‘Africa’ alone.
References cited in selected articles were reviewed for additional articles
and authors were contacted to obtain original data, where percentages but
not absolute numbers of resistant organisms were provided.
Studies were included if they tested E. coli, Klebsiella spp. or Salmonella
spp. for 3GC resistance. Methods of confirmatory ESBL testing, such as
double-disc synergy or PCR, were extracted from articles if they were
reported, but we did not exclude studies that did not confirm ESBL
status. We included surveillance data in addition to studies reporting
clinical cohorts, but excluded case reports, case series, expert opinions and
reviews.
Data extraction
Two authors (R.L. and P.M.) independently searched the literature and
screened the abstracts of all retrieved records. The full text of remaining
English articles was reviewed by one author (R.L.) and of French language
articles by another (N.V.G.). Articles in other languages were not found in
the search. Disputes about article inclusion were resolved through discus-
sion, with recourse to a third reviewer (N.A.F.) if required. Predefined varia-
bles were extracted from each article (Table 1). Variables included study
design and setting, clinical data such as age and HIV prevalence of clinical
cohorts, and information on laboratory methods including antimicrobial
susceptibility testing (AST) method and guideline, and method of ESBL con-
firmation. Mortality data were extracted as they were reported in the
articles, as case-fatality rates, ORs or relative risks (RRs).
Data analysis
Prevalence is described as proportions of 3GC-R isolates, calculated from
numbers of isolates of E. coli, Klebsiella spp., non-typhoidal Salmonella
(NTS) or Salmonella Typhi tested against a 3GC and the number of resistant
strains. Forest plots were generated, illustrating proportion estimates for
each study with 95% CI calculated using the Wilson’s score method. The I2
statistic was calculated to quantify heterogeneity.
Our initial analysis plan aimed to calculate a pooled proportion of 3GC
resistance for each pathogen, using random-effects meta-analysis with
subanalysis by African region. However, high levels of heterogeneity
amongst included studies precluded meaningful meta-analysis and we
therefore present median prevalence of 3GC resistance for each pathogen,
with corresponding IQR to provide an assessment of the wide range in re-
sistance prevalence. Medians were calculated for sSA and for each African
region as defined by the United Nations Statistics Division.9
Heterogeneity of proportion estimates was explored using predefined
subgroup analysis by African region and a post hoc subgroup analysis by
age group of study population. Visual inspection of resulting forest plots
was carried out and a test for subgroup differences applied where visual in-
spection suggested a likely difference in subgroup proportion estimates
and where more than two studies contributed to each subgroup. We add-
itionally examined for trends in proportions estimates over time using visual
inspection of forest plots, ordered by year of publication, and a linear meta-
regression model. Analyses were conducted using R version 3.5.1 (R
Foundation for Statistical Computing, Vienna, Austria).
Risk of bias assessment
In terms of delineating a population estimate, we noted that the most likely
risk of bias is patient selection. Additionally, the laboratory techniques and
their implementation may differ in sensitivity and specificity and could also
introduce bias. We modified the Critical Appraisal Skills Programme (CASP)
checklist to design a risk-of-bias assessment to fit our research question,
assessing risk of bias in patient recruitment and laboratory techniques used
(Table S4). The assessment was performed by both R.L. and P.M. and any
disagreements were resolved by consensus.
To explore for indirect evidence of publication bias, we examined 3GC re-
sistance estimates against the number of isolates included in the study, as
smaller studies may be subject to publication bias.
Results
The online database search combined with reference review from
key papers generated 1401 articles and, of these, 185 abstracts
were selected for full-text review (Figure 1). Original data for one
article were retrieved by direct communication with authors.10
Forty articles met the inclusion criteria and were included in the
systematic review, which synthesizes 11 404 isolates. Of these, 20
articles reported proportions of 3GC resistance in E. coli and 28 in
Klebsiella spp. Twelve studies reported proportions of 3GC resist-
ance in NTS and four in S. Typhi.
Table 1 presents the characteristics of all included studies. Data
were available from 12 countries across all four sSA regions
(Figure 2), with the highest proportion of studies (11/40) from
South Africa. All studies were observational. There were 30 studies
that recruited cohorts of patients with confirmed or suspected BSI,
16 of which were prospective, 13 retrospective and 1 mixed. Four
studies were cross-sectional reviews of isolates and three tested
isolates collected as part of longitudinal multisite surveillance.
There was one case–control study, designed to estimate mortality
from 3GC-R BSI.11
Systematic review
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Median estimates of 3GC resistance in E. coli, Klebsiella spp. and
salmonellae for sSA are shown in Table 2, together with median
estimates by African region, and forest plots of individual studies
are shown in Figures 3–5. The median point estimate of 3GC resist-
ance in E. coli BSI from 20 studies was 18.4% (IQR 10.5 to 35.2)
(Table 2). Heterogeneity was high (I2 = 93%) (Figure 3) and not
explained by prespecified subgroup analysis by African region
(Figure S1). Median point estimates of 3GC resistance in Klebsiella
BSI were higher across all regions than for E. coli, with an overall es-
timate of 54.4% (IQR 24.3 to 81.2) from 28 studies (Table 2,
Figure 4). As with E. coli, heterogeneity was high (I2 = 96%) and not
explained by differences in African region (Figure S1).
3GC resistance amongst NTS was low, at a median of 1.9% (IQR
0 to 6.1) in isolates from 12 studies (Figure 5). The highest propor-
tions of 3GC resistance in NTS came from eastern Africa (Kenya
and Mozambique) but subgroup analysis by African region did not
explain interstudy variability (Figure S1). Four studies in this review
carried out 3GC susceptibility testing on S. Typhi isolates.12–15 Of
these, two studies from Kenya12 and Tanzania14 found 3GC resist-
ance with prevalence of 6% (6/100) and 5.9% (1/17), respectively.
These studies did not report confirmatory ESBL testing on
cephalosporin-resistant S. Typhi strains.
The earliest published reports of 3GC resistance in Gram-
negative BSI are from 2002.16 Graphical exploration of forest plots,
ordered by year of publication (Figures 3–5), suggested a trend to-
wards increased 3GC resistance over time for Klebsiella, NTS and
E. coli. Meta-regression by year of publication supported a signifi-
cant trend towards increased resistance over time for Klebsiella
(P<0.01), NTS (P=0.02) and E. coli (P=0.02).
Studies reporting mortality estimates from 3GC-R BSI are
shown in Table 3. Only one study, a paediatric case–control study
in Senegal, was designed to determine attributable mortality from
3GC resistance as a primary outcome, finding that 3GC-R BSI
remained the only significant independent risk factor for death in
multivariable logistic regression, (OR=2.9, 95% CI 1.8–7.3,
P=0.001) regardless of antibiotic treatment choice.11 Seven further
studies10,17–22 provide mortality estimates for patients with 3GC-R
BSI, but were not designed to estimate attributable mortality from
these infections. These studies were a mixture of retrospective and
prospective designs, variably providing ORs, RRs and case-fatality
rates and incorporating different characteristics in multivariable
models. It was therefore not possible to combine these into a sin-
gle mortality estimate using meta-analysis. Where available,
case-fatality rates from individual studies were high, ranging from
60% to 100%, with all but one study concluding 3GC-R BSI to be a
predictor of fatal outcome in patients.
Additional study population characteristics are shown in
Table 1. There were 22 studies in paediatric populations, including
6 exclusively in neonates. Four studies recruited adults over
16 years of age, 13 recruited from all age groups and one study did
not report age of participants from which blood cultures were
obtained. Given that age categories were generally well reported
and could explain differences between proportion estimates, we
carried out post hoc stratified analysis by age group (Figure S2).
Visual inspection of resulting forest plots suggested no difference
in proportion estimates by age group for E. coli (Figure S2a), but po-
tentially higher proportion estimates for 3GC-R Klebsiella in chil-
dren than in adults (Figure S2b). A higher proportion estimate for
3GC resistance in NTS was seen in adults (Figure S2c) but there was
only one study in this age group.
Results of the risk-of-bias assessment are shown in Figure 6.
Bias in prevalence estimates was most likely introduced through
selection of study participants. Many studies did not report criteria
for blood culture sampling in the population recruited and many
were conducted in special populations such as neonatal ICUs
(NICUs). Most studies described blood culture methods well, but
few reported external quality control (QC) in laboratory methods,
resulting in a moderate risk of bias introduction across this domain
for most studies.
As a measure of potential publication bias, plots of 3GC resist-
ance estimates against study size, for E. coli and Klebsiella spp., are
1401 articles identified
through database
screening
85 duplicates excluded
1316 identified for title
and abstract screening
851 articles excluded on title
280 articles excluded on abstract
185 identified for
full-text screening
146 excluded after full-text
screening:
6 no denominators
2 no absolute numbers
24 no 3GS testing
67 not blood cultures
22 not separated by
specimen type
1 not separated by species
2 non-human samples
12 review articles
10 not sub-Saharan Africa
39 met eligibility criteria
1 additional study
identified by contact
with authors
40 included in
systematic review and
final analysis
Figure 1. Study selection.
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shown in Figure S2. For E. coli and Klebsiella, the larger studies
tended to report lower resistance estimates (Figure S3), suggesting
a potential for publication bias against studies reporting a smaller
number of isolates.
Blood culture processing techniques varied. An automated sys-
tem for blood culture incubation was used in 18 studies, whilst
manual systems were used in 10. Three studies reported a mixture
of manual and automated techniques and nine did not report
which methods were used. AST methods varied, but most labora-
tories used disc diffusion (22/40). Four studies used VITEK 2, with
the remainder using Etest, MicroScan or a mixture of techniques.
Three studies did not report which AST methods were used. Most
studies (30/40) used CLSI breakpoint guidelines, with the remain-
der using national or international guidelines as shown in Table 1.
Twenty-two studies carried out ESBL confirmatory testing in 3GC-R
isolates. Of these, 10 used double-disc synergy, with the remainder
using broth dilution, PCR or a mixture of methods.
The classification of isolates by source, for example whether
community-acquired (CA) or hospital-acquired (HA), or urban ver-
sus rural, is key to the interpretation of these data. Thirty studies
tested BSIs from patients presenting to public referral or private
hospitals in urban settings, with nine recruiting from rural district
hospitals and one from a mixed urban/rural setting. HIV status of
individuals who had blood culture sampling was recorded in only
11 studies and 1 study was exclusively a cohort of HIV-infected
individuals. Six studies investigated the difference in blood culture
pathogens and prevalence of resistance between CA and HA or
healthcare-associated (HCA) infection. Of these, five found a
higher prevalence of 3GC resistance in HA infections. Two studies
were cohorts of patients with HA infection and one study included
western Africa
10 studies, 5 countries
972 isolates
middle Africa
2 studies, 1 country
1173 isolates
southern Africa
11 studies, 1 country
5199 isolates
eastern Africa
1
1
5
2
1
2
2
7
6
1
1
11
17 studies, 5 countries
3767 isolates
Figure 2. Geographical location of studies reporting proportions of 3GC resistance amongst E. coli, Klebsiella spp. and NTS. Numbers in country indi-
cate the number of studies included in the review for each country. This figure appears in colour in the online version of JAC and in black and white in
the print version of JAC.
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Table 2. Median prevalence of 3GC resistance in E. coli, Klebsiella spp. and NTS BSI, shown by African region
Prevalence, % (IQR)
Pathogen overall 3GC resistance eastern middle western southern
E. coli 18.4 (10.5–35.2) 14.3 (10.0–24.3) no data 33.5 (25.0–51.6) 12.4 (12.1–22.2)
20 studies 9 studies 6 studies 5 studies
Klebsiella spp. 54.4 (24.3–81.2) 46.7 (17.3–84.5) no data 58.3 (34.6–82.6) 63.6 (39.1–76.2)
28 studies 10 studies 8 studies 10 studies
NTS 1.9 (0–6.1) 0 (0–9.6) 1.3, 6.3 4.8 (2.4–5.4) no data
12 studies 7 studies 2 studies 3 studies
First author, year
Bejon, 2005
Brink, 2007
Blomberg, 2007
Kohli, 2010
Ogunlesi, 2011
Mhada, 2012
Obeng–Nkrumah, 2013
Preziosi, 2015
Dramowski, 2015a
Onken, 2015
Wasihun, 2015
Seboxa, 2015
Dramowski, 2015b
Obeng–Nkrumah, 2016
Ndir, 2016
Eibach, 2016
Sangare, 2016
Musicha, 2017
Lochan, 2017
Crichton, 2018
Total
0
47
9
10
6
2
5
1
7
1
9
8
12
63
7
5
8
140
31
8
379
141
471
37
69
16
14
17
14
58
10
16
16
97
112
12
50
34
1311
90
36
2621
0.0
10.0
24.3
14.5
37.5
14.3
29.4
7.1
12.1
10.0
56.2
50.0
12.4
56.2
58.3
10.0
23.5
10.7
34.4
22.2
[0.0; 2.7]
[7.6; 13.0]
[13.4; 40.1]
[8.1; 24.7]
[18.5; 61.4]
[4.0; 39.9]
[13.3; 53.1]
[1.3; 31.5]
[6.0; 22.9]
[1.8; 40.4]
[33.2; 76.9]
[28.0; 72.0]
[7.2; 20.4]
[47.0; 65.1]
[4.3; 21.4]
[32.0; 80.7]
[12.4; 40.0]
[9.1; 12.5]
[25.4; 44.7]
[11.7; 38.1]
0 25 50
Proportion of 3GC–R (%)
75 100
Heterogeneity: I2 = 93%
Resistant Total strains Proportion (%) [95% CI]
Figure 3. Proportion of 3GC resistance in 2621 E. coli BSI isolates from 20 studies.
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only patients with suspected CA BSI. Of the six neonatal studies,
two differentiated early-onset from late-onset neonatal sepsis but
did not report on differences in proportions of 3GC resistance be-
tween the two groups.
Discussion
Our systematic review has synthesized over 11 000 blood culture
isolates from patients in sSA, finding high levels of 3GC resistance
amongst the key Enterobacteriaceae, E. coli and Klebsiella spp., and
emerging resistance amongst salmonellae. Ceftriaxone is one of the
most widely used broad-spectrum antibiotics in Africa, indicated in
the empirical management of adult and paediatric patients at dis-
trict-, regional- and tertiary-level care facilities.23–25 Limited access
to carbapenems and aminoglycosides may make 3GC-R BSI un-
treatable in some settings.8 The striking lack of mortality data we
describe in this review is therefore a major barrier to a comprehen-
sive understanding of the burden of AMR in this setting.
First author, year
Ko, 2002
Paterson, 2004
Bejon, 2005
Brink, 2007
Blomberg, 2007
Jaspan, 2008
Mshana, 2009
Kohli, 2010
Ogunlesi, 2011
Mhada, 2012
Obeng–Nkrumah, 2013
Acquah, 2013
Morkel, 2014
Perovic, 2014
Dramowski, 2015a
Dramowski, 2015b
Onken, 2015
Seboxa, 2015
Apondi, 2016
Buys, 2016
Obeng–Nkrumah, 2016
Ndir, 2016
Eibach, 2016
Sangare, 2016
Breurec, 2016
Musicha, 2017
Lochan, 2017
Marando, 2018
Total
3
20
6
293
9
0
29
5
13
4
13
1
10
1895
172
158
5
30
68
339
48
33
34
10
33
260
68
21
3580
40
76
63
636
53
13
31
38
33
22
26
12
17
2774
235
215
11
35
78
410
60
40
41
34
39
542
88
26
5688
7.5
26.3
9.5
46.1
17.0
0.0
93.5
13.2
39.4
18.2
50.0
8.3
58.8
68.3
73.2
73.5
45.5
85.7
87.2
82.7
80.0
82.5
82.9
29.4
84.6
48.0
77.3
80.8
[2.6; 19.9]
[17.7; 37.2]
[4.4; 19.3]
[42.2; 50.0]
[9.2; 29.2]
[0.0; 22.8]
[79.3; 98.2]
[5.8; 27.3]
[24.7; 56.3]
[7.3; 38.5]
[32.1; 67.9]
[1.5; 35.4]
[36.0; 78.4]
[66.6; 70.0]
[67.2; 78.4]
[67.2; 78.9]
[21.3; 72.0]
[70.6; 93.7]
[78.0; 92.9]
[78.7; 86.0]
[68.2; 88.2]
[68.1; 91.3]
[68.7; 91.5]
[16.8; 46.2]
[70.3; 92.8]
[43.8; 52.2]
[67.5; 84.8]
[62.1; 91.5]
0 25 75 10050
Proportion 3GC–R (%)
Heterogeneity: I2 = 96%
Resistant Total strains Proportion (%) [95% CI]
Figure 4. Proportion of 3GC resistance in 5688 Klebsiella spp. BSI isolates from 28 studies.
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We found a high median prevalence of 3GC resistance in E. coli
BSI, greater than estimates from high-income countries, which are
typically less than 10%.26 Interpreting the significance of propor-
tion estimates in the absence of trend data is challenging and the
latter will require long-term, high-quality surveillance. Some of the
most comprehensive published trend data come from Malawi,
where blood culture surveillance for 18 years has shown a recent,
rapid rise in 3GC resistance amongst Enterobacteriaceae in adult8
and paediatric patients.27 Between 2003 and 2016, the proportion
of 3GC-R E. coli rose from 0.7% to 30.3%, with similar trends in
other non-Salmonella Enterobacteriaceae.8 The alarming trends
described in Malawi highlight the urgent need for systematic AMR
surveillance data from Africa that will inform both policy on access
to antimicrobials and public health programmes aimed at reduc-
ing DRIs.
Resistance amongst Klebsiella spp., at 50.0%, was higher than
for E. coli. Klebsiella spp. frequently acquire AMR genes and are a
common cause of BSI in vulnerable populations, often causing
localized outbreaks in settings such as NICUs and paediatric ICUs
(PICUs).28 3GC-R Klebsiella spp. are a particular challenge in
neonatal infection as, in addition to the vulnerability of this age
group to severe bacterial infection, many antimicrobials are
either relatively contraindicated (e.g. chloramphenicol) or not
locally available as IV agents (e.g. ciprofloxacin). In the single
study from this review in which mortality from 3GC-R Klebsiella
was recorded, all patients died; clearly, prospective studies inves-
tigating transmission dynamics of this nosocomial pathogen are
required in order to support targeted interventions to reduce their
development and spread.21
Although resistance to first-line antimicrobials, such as ampicil-
lin, chloramphenicol and co-trimoxazole, is common among NTS
in sSA,29 3GC resistance has remained low, but may represent an
emerging problem (Figure 5).30 Our review found sporadic cases of
ceftriaxone resistance amongst S. Typhi from three countries, but
these studies did not carry out confirmatory testing for the pres-
ence of ESBL genes. Although not captured by our inclusion criteria,
ESBL-producing S. Typhi have been detected in sSA.31,32 In light
of the recent outbreak of fluoroquinolone-resistant and ESBL-
producing S. Typhi in Pakistan, resulting from the acquisition of
ESBL-encoding plasmids by the H58 haplotype (genotype 4.3.1)
known to be prevalent in Africa, this is concerning.33 Surveillance of
S. Typhi non-susceptibility in Africa will be essential, as emergence
of drug-resistant strains is associated with increase in transmissi-
bility of typhoid and resurgence of disease.34
We found marked heterogeneity amongst 3GC resistance
proportion estimates, which was not explained by differences in
African region or age group of patients. Prevalence of resistance
amongst key pathogens is likely to be influenced by a variety of
clinical parameters including HIV status, healthcare attendance
and prior antibiotic use, but these data were rarely reported and
subgroup analysis by these factors was impossible. Detailed clinical
and demographic parameters should be collected by studies that
aim to understand the epidemiology of DRIs and the drivers of
transmission of AMR pathogens.
We aimed to provide an estimate of the mortality burden from
3GC-R BSI, but this was prohibited by the scarcity of outcome data
and heterogeneity of study designs. DRIs are associated with ad-
verse patient outcomes in high-income settings, including high
First author, year
Bejon, 2005
Kariuki, 2006
Kariuki, 2006
Blomberg, 2007
Kohli, 2010
Kalonji, 2010
Lungunya, 2013
Labi, 2014
Maltha, 2014
Preziosi, 2015
Oneko, 2015
Eibach, 2016
Total
Heterogeneity: I2 = 93%
0
0
0
1
0
49
3
12
1
4
17
0
87
296
198
336
39
143
776
233
198
21
10
102
215
2567
0.0
0.0
0.0
2.6
0.0
6.3
1.3
6.1
4.8
40.0
16.7
0.0
[0.0; 1.3]
[0.0; 1.9]
[0.0; 1.1]
[0.5; 13.2]
[0.0; 2.6]
[4.8; 8.3]
[0.4; 3.7]
[3.5; 10.3]
[0.8; 22.7]
[16.8; 68.7]
[10.7; 25.1]
[0.0; 1.8]
0 25 50
Proportion of 3GC-R (%)
75 100
Resistant Total strains Proportion (%) [95% CI]
Figure 5. Proportion of 3GC resistance in 2567 NTS BSI isolates from 12 studies.
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mortality and increased length of hospital stay.35,36 In Africa,
where the prevalence of bacterial sepsis is high,4 late presentation
to secondary care is common and the availability of alternative
antimicrobials and advanced laboratory diagnostics is limited, the
impact of AMR on patients is predictable, but currently unknown.
This review has a number of limitations. Heterogeneity is highly
likely with reviews of this nature and the variety of populations
described make a true general population estimate difficult.
Potential sources of heterogeneity that we have not explored in-
clude the diversity of laboratory microbiological methods used,
both for organism identification and for AST. Most studies did not
report whether or how they engaged with external quality assur-
ance programmes. We did not exclude these from the review, as
they likely represent the vast majority of facilities in sSA, but this
may be an important source of variation in estimates.
Confirmatory testing for ESBL production using phenotypic or mo-
lecular methods is recommended for any organisms showing
reduced susceptibility to an indicator 3GC, but such confirmatory
methods were employed in just under half the studies included in
this review. However, resistance to 3GCs on primary screening tests
is sufficient evidence to infer 3GC resistance; therefore, again, we
did not exclude these studies from the analysis. Our assessment of
publication bias suggested a potential bias against publication of
studies reporting on a small number of isolates. However, the dif-
ferences in resistance estimates reported by studies of different
sizes are much more likely explained by differences in the included
populations, particularly since the majority of studies were not
designed to estimate resistance, but reported estimates as part of
blood culture surveillance or sepsis cohorts.
The limitations of available data we highlight in this review, to-
gether with the high level of unexplained interstudy heterogeneity,
prompt the need for standardization of AMR research. In future,
studies should be required to provide a clear account of the micro-
biological sampling criteria, study or surveillance sampling frame
and laboratory methods used to generate resistance data. Studies
should collect and report clinical metadata associated with the
sample, including empirical antibiotic regimens, HIV status and the
clinical setting, including level of the health system and intensity
of care. There are increasing efforts in the AMR surveillance com-
munity to identify exactly which data are minimally acceptable
and which data are ideal, to produce useful prevalence estimates
that contribute to global repositories such as the WHO’s Global
Antimicrobial Resistance Surveillance System (GLASS).37
We have documented proportions of 3GC-R BSI from a large
number of bloodstream isolates across sSA, expanding on previous
reviews that have focused on clinical syndromes,38 paediatric pop-
ulations39 or limited African regions.40 Using inclusion criteria that
captured surveillance studies in addition to clinical cohorts, we
have, to our knowledge, captured the largest AMR dataset avail-
able from sSA and therefore provide the most comprehensive
summary of 3GC-R BSI from the continent. In doing so, we demon-
strate the lack of available clinical data and show that the burden
of DRIs on patients in Africa remains unknown. Low-income coun-
tries have multiple, competing priorities for limited healthcare
resources and budgets, therefore clinicians, researchers and poli-
cymakers will need to demonstrate that AMR is a priority for
patients in these settings. This information does not currently exist
and AMR prevalence studies from sSA, however comprehensive,
will need to be accompanied by robust morbidity, mortality andN
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economic outcome data, to allow for a true understanding of the
burden of AMR on patients and health systems.
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